Aaron Ondrey's most recent trade in Rocket Pharmaceuticals Inc was a trade of 1,477 Common Stock done at an average price of $2.9 . Disclosure was reported to the exchange on July 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals Inc | Aaron Ondrey | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.88 per share. | 03 Jul 2025 | 1,477 | 128,173 (0%) | 0% | 2.9 | 4,257 | Common Stock |
| Rocket Pharmaceuticals Inc | Aaron Ondrey | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 5.29 per share. | 04 Apr 2025 | 7,489 | 129,650 (0%) | 0% | 5.3 | 39,647 | Common Stock |
| Rocket Pharmaceuticals Inc | Aaron Ondrey | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 134,642 | 134,642 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Aaron Ondrey | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 90,358 | 137,139 (0%) | 0% | 0 | Common Stock | |
| Rocket Pharmaceuticals Inc | Aaron Ondrey | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 69,337 | 69,337 | - | - | Stock Option (Right to Buy) | |
| Rocket Pharmaceuticals Inc | Aaron Ondrey | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 46,781 | 46,781 (0%) | 0% | 0 | Common Stock |